COVID vaccine clinical trials doomed to fail; fatal design flaw; NY Times opinion piece exposes all three major clinical trials.
Peter Doshi, associate editor of the medical journal BMJ, and Eric Topol, Scripps Research professor of molecular medicine, have written a devastating NY Times opinion piece about the ongoing COVID vaccine clinical trials.
They expose the fatal flaw in the large Pfizer, AstraZeneca, and Moderna trials.
September 22, the Times: “These Coronavirus Trials Don’t Answer the One Question We Need to Know”:
“If you were to approve a coronavirus vaccine, would you approve one that you only knew protected people only from the most mild form of Covid-19, or one that would prevent its serious complications?”
“The answer is obvious. You would want to protect against the worst cases.”
“But that’s not how the companies testing three of the leading coronavirus vaccine candidates, Moderna, Pfizer and AstraZeneca, whose U.S. trial is on hold, are approaching the problem.”
“According to the protocols for their studies, which they released late last week, a vaccine could meet the companies’ benchmark for success if it lowered the risk of mild Covid-19, but was never shown to reduce moderate or severe forms of the disease, or the risk of hospitalization, admissions to the intensive care unit or death.”
“To say a vaccine works should mean that most people no longer run the risk of getting seriously sick. That’s not what these trials will determine.”
This means these clinical trials are dead in the water.
The trials are designed to show effectiveness in preventing mild cases of COVID, which nobody should care about, because mild cases naturally run their course and cause no harm. THERE IS NO NEED FOR A VACCINE THAT PREVENTS MILD CASES.
That’s the NY Times one-off.
My piece analyzing it went on much longer, but you get the main thrust:
The leading vaccine clinical trials are useless, irrelevant, misleading, and deceptive.
But now, it gets much worse. Because Pfizer has just announced their vaccine is almost ready. CNBC headline, November 9: “Pfizer, BioNTech say Covid vaccine is more than 90% effective—‘great day for science and humanity’”.
And not a peep about the NY Times one-off. That’s gone, as if it never was.
Trump’s coronavirus task force knows the truth. Biden’s new task force, waiting in the wings, knows the truth. But they don’t care. They’re criminals. They’d sell a car with a gas tank ready to explode to a customer with cash.
But you care, because you can read and think.
You can raise hell.
Now, in case anyone is interested in knowing WHY the major clinical trials of the COVID vaccine are designed only to prevent mild cases of COVID, I’ll explain.
A vaccine maker assumes that, during the course of the clinical trial, a few of the 30,000 volunteers are going to “catch COVID-19.”
They assume this because “the virus is everywhere,” as far as they’re concerned. So it’ll drop down from the clouds and infect a few of the volunteers.
The magic number is 150. When that number of volunteers “catch COVID,” everything stops. The clinical trial stops.
At this point, the vaccine maker hopes that most of the volunteers who “got infected” are in the placebo group. They didn’t receive the real vaccine; they received the saltwater placebo shot.
Then the vaccine maker can proudly say, “See? The volunteers who caught COVID-19? Most of them didn’t receive the vaccine. They weren’t protected. The volunteers who received the real vaccine didn’t catch COVID. The vaccine protected them.”
Actually, the number split the vaccine makers are looking for is 50 and 100. If 50 people in the vaccine group catch COVID, and 100 in the placebo group catch COVID, the vaccine is said to be 50% effective. And that’s all the vaccine maker needs to win FDA approval for the vaccine.
But wait. Let’s look closer at this idea of “catching COVID.” What are they really talking about? How do they define that? Claiming a volunteer in the clinical trial caught COVID adds up to what?
Does it add up to a minimal definition of COVID-19—a cough, or chills and fever? Or does it mean a serious case—severe pneumonia?
Now we come to the hidden factor, the secret, the source of the whole con game.
You see, the vaccine maker starts out with 30,000 HEALTHY volunteers. So, if they waited for 150 of them to come down with severe pneumonia, a serious case of COVID, how long do you think that would take? Five years? Ten years?
The vaccine maker can’t possibly wait that long.
These 150 COVID cases the vaccine maker is looking for would be mild. Just a cough. Or chills and fever. That scenario would only take a few months to develop. And face it, chills, cough, and fever aren’t unique to COVID. Anyone can come down with those symptoms.
THEREFORE, THE WHOLE CLINICAL TRIAL IS DESIGNED, UP FRONT, TO FIND 150 CASES OF MILD AND MEANINGLESS AND SELF-CURING “COVID.”
About which, no one cares. No one should care.
But, as we see, Pfizer is trumpeting their clinical trial of the vaccine as a landmark in human history.
And THAT’S the story of the one-off the NY Times didn’t think was worth a second glance.
Because they’re so stupid? No. They’re not that stupid.
And the government wants you to take the experimental COVID vaccine, whose “effectiveness” was designed to prevent nothing worth losing a night’s sleep over.
The only worry are the adverse effects of the vaccine, about which I’ve written extensively. These effects include, depending on what’s in the vial, a permanent alteration of your genetic makeup, or an auto-immune cascade, in which the body attacks itself.
(The link to this article posted on my blog is here — with sources.)
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.